Already approved for progressive multiple sclerosis, ocrelizumab in a second phase 3 study demonstrates meaningful clinical ...

Comparatives, the leading independent cybersecurity testing lab, today announced the results of its 2025 Endpoint Prevention ...

Small and medium-sized businesses (SMBs) are accelerating their digital transformation by embracing cloud technologies and AI ...

Global glass packaging company PGP Glass embarked on a multiyear effort to modernize its OT and IoT infrastructure, ...

AttackIQ has released two new assessment templates in response to the CISA Advisory (AA25-266A) published on September 23, 2025. The CSA highlights the lessons learned from an incident response ...

The 25 items you might own that just might be worth a fortune Countless individuals have discovered extraordinary treasures ...

The resulting report, Third-Party Cyber Risks to Global Supply Chains: An Assessment of Key Indian Suppliers, found that 53% ...

Generative artificial intelligence isn't just a new tool—it's a catalyst forcing the higher education profession to reimagine ...

Pharmaceutical companies face increasing pressure to demonstrate not only the efficacy of their treatments, but also the impact of these treatments on patients' lives. This interest in and the ...

The Relative Strength Index (RSI) indicator on the 4-hour chart declines toward 50 and EUR/USD struggles to pull away from the 20-period Simple Moving Average (SMA) after clearing this level on ...

The phase III Radiotherapy Comparative Effectiveness (RadComp) trial enrolled more than 1,200 patients, making it also the largest head-to-head comparison of photon and proton therapy for any cancer ...